Sign in
4

Changes in Ownership

Adaptive Biotechnologies Corp Filed Acc 0001209191-20-061326

Chief Business Development Off sold 6,770 shares at an average $48.87 ($330,856)

  • Chief Business Development Off acquired 6,770 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-12-01 Option exercise +2,604 $6.55 $17,056 2,604 D: show line 1 in the form
BENZENO SHARON Chief Business Development Off 2020-12-01 Option exercise +2,604 $6.55 $17,056 5,208 D: show line 2 in the form
BENZENO SHARON Chief Business Development Off 2020-12-01 Option exercise +1,562 $7.27 $11,356 6,770 D: show line 3 in the form
BENZENO SHARON Chief Business Development Off 2020-12-01 Sale −3,077 $48.20 $148,311 3,693 D: show line 4 in the form
BENZENO SHARON Chief Business Development Off 2020-12-01 Sale −3,693 $49.43 $182,545 0 D: show line 5 in the form
Open-market sales · 6,770 sh · avg $48.87 · $330,856

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
BENZENO SHARON Chief Business Development Off 2020-12-01 Option exercise · Stock Option (Right to Buy) −2,604 28,646 D: show line 6 in the form
BENZENO SHARON Chief Business Development Off 2020-12-01 Option exercise · Stock Option (Right to Buy) −2,604 57,292 D: show line 7 in the form
BENZENO SHARON Chief Business Development Off 2020-12-01 Option exercise · Common Stock (Right to Buy) −1,562 39,063 D: show line 8 in the form
Loading xslF345X03/doc4.xml…